Summary & Overview
HCPCS Level II J9200: Injection, floxuridine, 500 mg
HCPCS Level II code J9200 identifies the 500 mg vial for floxuridine, an antineoplastic injection used in chemotherapy regimens. This code is important for accurate drug billing and payment for intravenous cancer treatments administered in outpatient and infusion settings. Proper use of J9200 affects facility and payer reimbursement for drug acquisition and administration costs and has implications for inventory and clinical workflow in oncology services.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a national overview of billing context for J9200, including typical sites of service, common modifier practices, and benchmarking notes where available. The publication outlines how J9200 fits into chemotherapy service lines, summarizes payer coverage considerations, and highlights operational implications for hospital outpatient departments and ambulatory infusion centers.
This summary provides clinicians, billing professionals, and policy analysts with the clinical context for floxuridine billing, what to expect in claims processing, and where to look for additional reimbursement and coding guidance. Data not available in the input is noted where relevant.
Billing Code Overview
HCPCS Level II code J9200 represents an injection of floxuridine, 500 mg. This code denotes the administration of the chemotherapeutic agent floxuridine in a 500 mg dosage unit.
Service Type: Chemotherapy drug administration (antineoplastic agent)
Typical Site of Service: Hospital outpatient department or ambulatory infusion center
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with a diagnosed metastatic gastrointestinal malignancy (commonly colorectal or hepatic metastases) receiving regional or systemic chemotherapy. The service described by J9200 (injection, floxuridine, 500 mg) is administered in an outpatient infusion center, hospital outpatient department, or ambulatory surgical center by an oncology team. The clinical workflow includes: pre-visit assessment (vital signs, lab review for hepatic and bone marrow function), verification of the chemotherapy order and dose calculation by the oncologist and pharmacist, preparation of floxuridine under sterile conditions by pharmacy, placement or verification of vascular access (peripheral IV or implanted port), administration of the infusion by an RN with oncology training, monitoring for infusion reactions and toxicities during and after administration, documentation of lot numbers and waste when applicable, and post-infusion discharge instructions and scheduling of follow-up labs and oncology visits.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier — standard billing | Use when no special circumstances apply to the service. |